Genesis Therapeutics was officially founded in 2019 by Evan Feinberg and Ben Sklaroff, emerging out of advanced computational research originating at Stanford University. The biotechnology enterprise was established with the core mission of revolutionizing small molecule drug discovery by building advanced artificial intelligence and physics-based machine learning platforms designed to tackle previously undruggable biological targets for patients suffering from severe and underserved diseases.